Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Chugai Files NDA for Antibody-Drug Conjugate T-DM1 for HER2-Positive Breast Cancer
January 31, 2013
- Higher Dose of Toviaz Further Reduces Urge Urinary Incontinence in Patients with OAB: Pfizer
January 31, 2013
- TS-1 Superior to Gemcitabine in Extending OS of Resected Pancreatic Cancer Patients in PIII Study: Taiho
January 30, 2013
- No New Safety Concerns Found in All-Case PMS of Vectibix: Takeda
January 30, 2013
- “Hybrid” Bioventures Might Help Japanese Pharmas Compete in the Global Market: Prof. Kneller
January 30, 2013
- Number of MR-Qualified MSs Reaches 840 with 376 Newly Passing MR Exam: Medipal Group
January 30, 2013
- Nesina Approved in US: Takeda
January 29, 2013
- Medipal Group Introduces Special Mini Cooler for New Orphan Drug
January 29, 2013
- Kyowa Kirin to Apply for KRN125 in 2013
January 28, 2013
- Ono, DSP Cancel Development of Limaprost for CTS
January 28, 2013
- Novartis AG: Annual Sales Down, Profits Up, Gilenya Reaches Blockbuster Status
January 28, 2013
- Market for Novel Oral Anticoagulants to Heat Up as More Companies Compete for Low-risk Patients
January 28, 2013
- Otsuka to Hire 55 Grads of 6-Year Pharmaceutical Universities as MRs in FY2013: Jiho Poll
January 25, 2013
- Novartis, Sanofi Dissolve Partnership on Equa Copromotion
January 25, 2013
- AIMIX Ranks No.1, Lotriga Soars in GP Market: Rep Track Survey
January 25, 2013
- JSMI Chief Yoshino Voices Disagreement with JMA on Epadel OTCs
January 25, 2013
- Transparency GL: Drug Makers Might Disclose Individual Payments Only Upon Request
January 24, 2013
- Takeda Establishes Trading Company in China to Serve as Base for Import of Finished Products
January 24, 2013
- Bayer, Santen Aim to Lead Market with Simpler Eylea Administration
January 24, 2013
- Merck Serono Aims for Top 10 Slot in Oncology Field
January 23, 2013
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…